This information is intended for use by health professionals
Nutraplus 10% w/w Cream
Each gram of cream contains 100mg of Urea
Excipients with known effect: Methyl parahydroxybenzoate (E218) 1.8 mg/g, Propyl parahydroxybenzoate (E216) 0.9 mg/g, Propylene glycol 45mg/g, Cetearyl alcohol 18.0 mg/g – 22.5 mg/g
For the full list of excipients see section 6.1
Smooth white, almost odourless cream (water in oil emulsion).
An emollient, moisturising and protective cream for the treatment of dry or damaged skin
Adults, paediatric population and older people
Apply evenly to the dry skin areas two to three times daily, or as directed by the physician or pharmacist.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
The product should not be used extensively in patients with severe renal impairment.
Avoid contact with the eyes and mucous membranes. If irritation occurs, discontinue use temporarily and consult a physician.
Apply with caution only to damaged or inflamed skin or to the face.
The product should be used under medical supervision in babies.
Urea may enhance the efficacy of topical formulations of 5-fluorouracil and dithranol, and increase the release and the permeation into the skin of active ingredients from other topical products such as corticosteroids.
There are no clinical data available concerning use in pregnancy.
There are no adequate experimental animal studies available concerning the effects on pregnancy, embryonic development, foetal development and/or post-natal development.
Caution must be exercised for use during pregnancy. However, indications of risks associated with topical applications of urea during pregnancy and while breast-feeding are not known.
In breast-feeding women, the product should be removed from the breast area before breast-feeding.
Nutraplus has no or negligible influence on the ability to drive and use machines.
Skin and subcutaneous tissue
Hypersensitivity reactions to the ingredients or skin irritation in the treatment of acute inflammatory skin disorders are possible.
Erythema, skin burning sensation and pruritus have been reported during post-marketing surveillance.
Treatment must be discontinued in case of erythema, skin burning sensation, pruritus, rash or hypersensitivity reactions after application.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard
Intoxication after the use of Nutraplus is not known and is not to be expected due to the composition of the preparation. Skin irritation caused by overdose subsides quickly when the preparation is discontinued.
Pharmacotherapeutic group: Protectives and emollients.
ATC code: D02 AE01
Urea is a recognised hydrating agent that has been widely used topically to treat dry or damaged skin.
Not applicable. Nutraplus is a topical (cutaneous) preparation.
No specific information is presented given the widespread use of topically applied urea on humans over many years.
Promulgen D (contains Cetearyl alcohol and ceteareth-20)
Propyl parahydroxybenzoate (E216)
Methyl parahydroxybenzoate (E218)
Do not store above 25°C.
As with all medicines, Nutraplus Cream should be stored out of the sight and reach of children.
White, polyethylene tube with a white polypropylene screw cap as the closure.
Pack sizes: 60g and 100g
Not all pack sizes may be marketed.
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Galderma (UK) Limited
69-71 Clarendon Road
04th June 1991
31st July 2017